Prognostic value of JAK2V617F mutation in pseudotumor cerebri associated with cerebral venous sinus thrombosis

被引:4
|
作者
Zloto, Ofira [1 ,2 ]
Lubetsky, Aharon [3 ]
Mizrachi, Iris Ben-Bassat [2 ]
Kesler, Anat [1 ]
Quiros, Peter A. [4 ]
Huna-Baron, Ruth [1 ,2 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[2] Sheba Med Ctr, Neuroophthalmol Unit, Tel Hashomer, Israel
[3] Sheba Med Ctr, Thrombosis & Hemostasis Unit, Tel Hashomer, Israel
[4] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA
来源
ACTA NEUROLOGICA SCANDINAVICA | 2019年 / 139卷 / 02期
关键词
cerebral venous sinus thrombosis; JAK2V617F mutation; pseudotumor cerebri; JAK2 V617F MUTATION; POLYCYTHEMIA-VERA; THROMBOEMBOLISM; RISK;
D O I
10.1111/ane.13032
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives To examine the clinical characteristics and prognosis of cerebral venous sinus thrombosis (CVST) that presented as pseudotumor cerebri (PTC) patients with JAK2V617F mutation. Methods Medical records of all consecutive patients that presented with PTC and a JAK2V617F mutation who were treated were retrospectively reviewed. Data regarding demographics and ocular presenting symptoms and signs, neurological signs, hematological factors treatment, and prognosis were collected. Results The most common presenting symptoms were headache (5 patients, 83.3%) and visual obscurations (5 patients, 83.3%). CVST of the sagittal sinus and sigmoid sinus were the most common site of thrombus. Platelet count and hemoglobin count were higher than normal during follow-up. There was significant change in the disk edema degree as well as decline in retinal nerve fiber layer (RNFL) thickness (P < 0.001, P < 0.001, Matched pairs). There was no significant change in visual acuity (VA) or mean deviation (MD) during follow-up (P = 0.95, 0.64, respectively, Matched pairs). Conclusions Pseudotumor cerebri resulting from CSVT in our patients with JAK2V617F mutation was frequent in young patients and needed medical and surgical treatment, without improvement in visual functions and in third caused poor visual outcome. Therefore, we believe that a screening test for JAK2V617F mutation should be considered for patients with CVST without known risk factor presenting with PTC, especially when sagittal sinus or sigmoid sinus involvement or thrombocytosis or high hemoglobin are found upon presentation. This might lead to more aggressive management which may improve the visual prognosis of those young patients.
引用
收藏
页码:166 / 171
页数:6
相关论文
共 50 条
  • [41] Generalized Chorea and JAK2V617F Mutation-Positive Myeloproliferative Disorders
    Bette, Sagari
    Moore, Henry
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2020, 7 (04): : 462 - 463
  • [42] JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
    Santos, Fabio P. S.
    Verstovsek, Srdan
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (09) : 1098 - 1109
  • [43] The JAK2V617F mutation: no impact on circulating hematopoietic progenitors in myeloproliferative disorders
    Michaela Wappl
    Eva Jaeger
    Raiko Kusec
    Ilse Schwarzinger
    Klaus Geissler
    Leopold Oehler
    Annals of Hematology, 2008, 87 : 509 - 511
  • [44] Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation
    Jurisic, Vladimir
    Pavlovic, Sonja
    Colovic, Natasa
    Colovic, Milica
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [45] Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation
    Vladimir Jurisic
    Sonja Pavlovic
    Natasa Colovic
    Milica Colovic
    Medical Oncology, 2013, 30
  • [46] The JAK2V617F mutation in normal individuals takes place in differentiating cells
    Krichevsky, Svetlana
    Prus, Eugenia
    Perlman, Riki
    Fibach, Eitan
    Ben-Yehuda, Dina
    BLOOD CELLS MOLECULES AND DISEASES, 2017, 63 : 45 - 51
  • [47] Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F
    Misaka, Tomofumi
    Kimishima, Yusuke
    Yokokawa, Tetsuro
    Ikeda, Kazuhiko
    Takeishi, Yasuchika
    JOURNAL OF CARDIOLOGY, 2023, 81 (01) : 3 - 9
  • [48] Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis
    Colaizzo, Donatella
    Tiscia, Giovanni Luca
    Bafunno, Valeria
    Amitrano, Lucio
    Vergura, Patrizia
    Lupone, Maria Rosaria
    Grandone, Elvira
    Guardascione, Maria Anna
    Margaglione, Maurizio
    THROMBOSIS RESEARCH, 2011, 128 (03) : 233 - 236
  • [49] JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate
    Nielsen, Camilla
    Bojesen, Stig E.
    Nordestgaard, Borge G.
    Kofoed, Klaus F.
    Birgens, Henrik S.
    HAEMATOLOGICA, 2014, 99 (09) : 1448 - 1455
  • [50] JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses
    Gonzalez-Montero, Jaime
    Del Valle-Batalla, Lucia
    Castillo-Astorga, Raul
    Marin Valdes, Arnaldo
    Conte Lanza, Guillermo
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2020, 42 (03) : 331 - 334